Piper Jaffray Companies set a $10.00 price target on Insys Therapeutics, Inc. (NASDAQ:INSY) in a research note released on Wednesday. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.

A number of other brokerages also recently commented on INSY. Royal Bank Of Canada set a $16.00 price objective on Insys Therapeutics and gave the company a buy rating in a research report on Saturday, June 3rd. Zacks Investment Research upgraded Insys Therapeutics from a sell rating to a strong-buy rating and set a $15.00 price objective for the company in a research report on Wednesday, July 12th. BidaskClub upgraded Insys Therapeutics from a hold rating to a buy rating in a research report on Saturday, July 8th. Oppenheimer Holdings, Inc. reiterated a hold rating on shares of Insys Therapeutics in a research report on Tuesday, July 4th. Finally, Jefferies Group LLC reiterated a buy rating and set a $14.00 price objective on shares of Insys Therapeutics in a research report on Friday, June 9th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $13.75.

Insys Therapeutics (INSY) opened at 11.39 on Wednesday. The firm’s 50-day moving average price is $12.34 and its 200 day moving average price is $11.45. The stock’s market cap is $821.50 million. Insys Therapeutics has a 52-week low of $8.70 and a 52-week high of $19.96.

Insys Therapeutics (NASDAQ:INSY) last announced its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Insys Therapeutics had a negative return on equity of 0.97% and a negative net margin of 2.64%. The company had revenue of $35.92 million during the quarter, compared to the consensus estimate of $37.78 million. During the same quarter in the prior year, the firm earned $0.11 EPS. The company’s quarterly revenue was down 40.5% compared to the same quarter last year. Equities analysts predict that Insys Therapeutics will post ($0.47) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/piper-jaffray-companies-analysts-give-insys-therapeutics-inc-nasdaqinsy-a-10-00-price-target/1462171.html.

In other Insys Therapeutics news, Director Steven J. Meyer bought 8,000 shares of Insys Therapeutics stock in a transaction dated Thursday, May 18th. The stock was bought at an average price of $12.21 per share, for a total transaction of $97,680.00. Following the completion of the acquisition, the director now directly owns 52,083 shares of the company’s stock, valued at $635,933.43. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Saeed Motahari bought 5,400 shares of Insys Therapeutics stock in a transaction dated Wednesday, June 14th. The stock was acquired at an average price of $11.10 per share, with a total value of $59,940.00. Following the acquisition, the chief executive officer now directly owns 9,900 shares of the company’s stock, valued at $109,890. The disclosure for this purchase can be found here. Insiders bought 21,900 shares of company stock valued at $268,090 in the last 90 days. Corporate insiders own 67.90% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in INSY. American International Group Inc. raised its stake in Insys Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,462 shares of the specialty pharmaceutical company’s stock worth $152,000 after buying an additional 953 shares during the last quarter. UBS Asset Management Americas Inc. bought a new position in Insys Therapeutics during the first quarter worth $172,000. Janney Montgomery Scott LLC bought a new position in Insys Therapeutics during the first quarter worth $188,000. Bank of Montreal Can increased its position in Insys Therapeutics by 215.3% in the first quarter. Bank of Montreal Can now owns 20,812 shares of the specialty pharmaceutical company’s stock worth $219,000 after buying an additional 14,212 shares during the period. Finally, Parametric Portfolio Associates LLC increased its position in Insys Therapeutics by 34.5% in the first quarter. Parametric Portfolio Associates LLC now owns 25,712 shares of the specialty pharmaceutical company’s stock worth $270,000 after buying an additional 6,600 shares during the period. Institutional investors own 28.18% of the company’s stock.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.